GRAIL is trading at $70.12 (-5.47%) in pre-market as the initial positive reaction to its Q2 earnings report reversed due to concerns over monetization.
- The company reported $44.7 million in Q2 revenue, but investors flagged a significant gap between volume and sales growth.
- While Galleri test volume grew by 35%, revenue only increased by 24%, signaling potential pricing pressure on its flagship product.
- The disparity has raised analyst concerns regarding the company's long-term ability to effectively monetize its diagnostic technology.